Historical Development of Monoclonal Antibody Therapeutics

  • A. Nissim
  • Y. Chernajovsky
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 181)

Since the first publication by Kohler and Milstein on the production of mouse monoclonal antibodies (mAbs) by hybridoma technology, mAbs have had a profound impact on medicine by providing an almost limitless source of therapeutic and diagnostic reagents. Therapeutic use of mAbs has become a major part of treatments in various diseases including transplantation, oncology, autoimmune, cardiovascular, and infectious diseases. The limitation of murine mAbs due to immunogenicity was overcome by replacement of the murine sequences with their human counterpart leading to the development of chimeric, humanized, and human therapeutic antibodies. Remarkable progress has also been made following the development of the display technologies, enabling of engineering antibodies with modified properties such as molecular size, affinity, specificity, and valency. Moreover, antibody engineering technologies are constantly advancing to enable further tuning of the effector function and serum half life. Optimal delivery to the target tissue still remains to be addressed to avoid unwanted side effects as a result of systemic treatment while achieving meaningful therapeutic effect.


West Nile Virus Effector Function Phage Display Antibody Fragment Human Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andrew P, Chapman PA, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780-783CrossRefGoogle Scholar
  2. Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 91:3809-3813CrossRefPubMedGoogle Scholar
  3. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME (2005) Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-humaninterleukin-13 antibody (CAT-354). Clin Exp Allergy 35:1096-1103CrossRefPubMedGoogle Scholar
  4. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305(5681):200-205CrossRefPubMedGoogle Scholar
  5. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553-557CrossRefPubMedGoogle Scholar
  6. Borghaei H, Schilder RJ (2004) Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 34:4-9CrossRefPubMedGoogle Scholar
  7. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643-646CrossRefPubMedGoogle Scholar
  8. Cambridge G, Leandro M, Edwards J, Ehrenstein M, Salden M, Bodman-Smith M, Webster A (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146-2154CrossRefPubMedGoogle Scholar
  9. Carlos Vaccaro JZ, Ober RJ, Wardl ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283-1288CrossRefPubMedGoogle Scholar
  10. Carter P (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357CrossRefPubMedGoogle Scholar
  11. Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531-545CrossRefPubMedGoogle Scholar
  12. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932PubMedGoogle Scholar
  13. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535-539CrossRefPubMedGoogle Scholar
  14. de Kruif J, Baker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J. Crucell Holland BV, Leiden, (2007) A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis. Annu Rev Med 58:359-368CrossRefPubMedGoogle Scholar
  15. de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM (2000) Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol 18:989-994CrossRefPubMedGoogle Scholar
  16. Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26:52-57PubMedGoogle Scholar
  17. Choy EHS, Smith1 BHM, Moss K, Lisi L, Scott DGI, Patel4 J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41:1133-1137CrossRefPubMedGoogle Scholar
  18. Eiermann W (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(Suppl 1):S57-S62CrossRefPubMedGoogle Scholar
  19. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690CrossRefPubMedGoogle Scholar
  20. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 9:600-607CrossRefGoogle Scholar
  21. Gardner K (2006) Cytokine storm and an anti-CD28 monoclonal antibody. N Engl J Med 355:2593-2594CrossRefGoogle Scholar
  22. Ghetie Vea (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640CrossRefGoogle Scholar
  23. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, Super M, Lo KM (1998) Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 160:6195-6203PubMedGoogle Scholar
  24. Gillies SD, Reilly EB, Lo KM, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428-1432CrossRefPubMedGoogle Scholar
  25. Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA (1991) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10:347-356CrossRefPubMedGoogle Scholar
  26. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo J 13:3245-3260PubMedGoogle Scholar
  27. Hanes J, Pluckthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94:4937-4942CrossRefPubMedGoogle Scholar
  28. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsurushita N (2004) Engineered human IgG antibodies with longer serum halflives in primates. J Biol Chem 279:6213-6216CrossRefPubMedGoogle Scholar
  29. Harrison JL, Williams SC, Winter G, Nissim A (1996) Screening of phage antibody libraries. Methods Enzymol 267:83-109CrossRefPubMedGoogle Scholar
  30. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484-490CrossRefPubMedGoogle Scholar
  31. Hoogenboom H (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-1116CrossRefPubMedGoogle Scholar
  32. Hudson PHPJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136CrossRefPubMedGoogle Scholar
  33. Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10CrossRefPubMedGoogle Scholar
  34. Idusogie EE, Wong P, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166:2571-2575PubMedGoogle Scholar
  35. Jakobovits A, Moore AL, Green LL, Vergara GJ, Maynard-Currie CE, Austin HA, Klapholz S (1993) Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature 362:255-258CrossRefPubMedGoogle Scholar
  36. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementaritydetermining regions in a human antibody with those from a mouse. Nature 321:522-525CrossRefPubMedGoogle Scholar
  37. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622-631PubMedGoogle Scholar
  38. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497CrossRefPubMedGoogle Scholar
  39. Kreitman RJ (1999) Immunotoxins in cancer therapy. Curr Opin Immunol 11:570-578CrossRefPubMedGoogle Scholar
  40. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636PubMedGoogle Scholar
  41. Kress A (2002) Adalimumab - for use in the treatment of rheumatoid arthritis: clinical review. Abbott Laboratories Biologic Licensing Application, 1-136. Office of Therapeutics Research and Review; Division of Clinical Trial Design and Analysis; Immunology and Infectious Disease BranchGoogle Scholar
  42. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010CrossRefPubMedGoogle Scholar
  43. Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176-182CrossRefPubMedGoogle Scholar
  44. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125CrossRefPubMedGoogle Scholar
  45. Maas RA, Dullens HF, Den Otter W (1993) Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 36:141-148CrossRefPubMedGoogle Scholar
  46. Marks J (2004) Antibody affinity maturation by chain shuffling. Methods Mol Biol 248:327-343PubMedGoogle Scholar
  47. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonz ález Trotter DE, Adams GP (2005) Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 Diabody. Cancer Res 65:1471-1478CrossRefPubMedGoogle Scholar
  48. McWhirter JR, K.-R.A., Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS, Alexion Antibody Technologies I (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 1003:1041-1046Google Scholar
  49. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349-1363PubMedGoogle Scholar
  50. Morris PJ, Russell N (2006) Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81:1361-1367CrossRefPubMedGoogle Scholar
  51. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271-1275CrossRefPubMedGoogle Scholar
  52. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G (1994) Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. Embo J 13:692-698PubMedGoogle Scholar
  53. Padlan EA (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28:489-498CrossRefPubMedGoogle Scholar
  54. Reichmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332(6162):323-327CrossRefGoogle Scholar
  55. Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135:1530-1535PubMedGoogle Scholar
  56. Shields RL et al. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276:6591-6604CrossRefPubMedGoogle Scholar
  57. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5:2340-2350CrossRefPubMedGoogle Scholar
  58. Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758CrossRefPubMedGoogle Scholar
  59. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80(14):6982-6992PubMedGoogle Scholar
  60. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309-314CrossRefPubMedGoogle Scholar
  61. von Mehren M, Adams G, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343-369CrossRefPubMedGoogle Scholar
  62. Wahl R (2005) Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J Nucl Med 46(Suppl 1):128S-140SPubMedGoogle Scholar
  63. Ward S, Mandez C, Vaccaro C, Zhou J, Tang Q, Ober RJ (2005) From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16:2028-2038CrossRefPubMedGoogle Scholar
  64. Weinblatt E, Ketystone C, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum 48:35-45CrossRefPubMedGoogle Scholar
  65. Winter G, G.A., Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433-455CrossRefPubMedGoogle Scholar
  66. Wu AM, Senter P (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146CrossRefPubMedGoogle Scholar
  67. Zhang W, Feng J, Li Y, Guo N, Shen B (2005) Humanization of an anti-human TNF-a antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol 42:1445-1451CrossRefPubMedGoogle Scholar
  68. Zhao L, Rai SK, Grosmaire LS, Ledbetter JA, Fell HP (1999) Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF. J Hematother Stem Cell Res 8: 393-399CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • A. Nissim
    • 1
  • Y. Chernajovsky
    • 1
  1. 1.Bone and Joint Research UnitWilliam Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of LondonLondonUK

Personalised recommendations